VEGFA and metastatic colorectal cancer: The results from genotyping angiogenesis-related genes show that only VEGFA variant rs2010963 maintains an independent correlation with progression-free and overall survival in these patients [153], which has led researchers to propose VEGFA rs2010963 genotyping as a useful tool for a more accurate selection of optimal candidates for regorafenib therapy among metastatic colorectal cancer patients [153].